Dulanermin

Drug Profile

Dulanermin

Alternative Names: AMG-951; PRO 1762; Recombinant human Apo2L/TRAIL; RG 3639; Rh-Apo2L - Amgen/Genentech; rhApo2L/TRAIL; TNF-related apoptosis-inducing ligand; TRAIL/Apo2L

Latest Information Update: 21 Jun 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; Genentech
  • Class Antineoplastics; Recombinant proteins
  • Mechanism of Action Apoptosis stimulants; TRAIL receptor 1 agonists; TRAIL receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 26 Jul 2011 Discontinued - Phase-I for Colorectal cancer in USA (IV)
  • 15 Jun 2011 Genentech and Amgen terminate a phase I/II trial in Non-Hodgkin's lymphoma in Australia, European Union, New Zealand and USA(NCT00400764)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top